CREATE Medicines Inc., a clinical-stage biotechnology company pioneering in vivo multi-immune programming, today announced ...
In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a ...
Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...
Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference December 8, 2025 8:00 ...
Gen Z and Millennials are reshaping the mental health narrative in 2025 by encouraging open conversations, prioritizing ...
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) ...
For decades, the state has offered limited avenues for rehabilitation and shorter sentences. It’s time lawmakers fix it.
Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients ...
Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards ...
Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...
VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery platforms existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback